# Peginterferon alfa-2a

Peginterferon alfa-2a (Pegasys, pharmaand GmbH) has 1 EU-approved indication in 1 tumour type.

## Approved indications

### Myeloproliferative neoplasms

| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| None | Monotherapy | Any line | Polycythaemia vera or essential thrombocythaemia only |

## Products

### Pegasys

- Company: pharmaand GmbH
- Target: Pegylated interferon alfa
- ATC: L03AB11
- EU approval: 20 Jun 2002
- Label revised: 22 Sep 2026
- SmPC (EN): https://www.ema.europa.eu/en/documents/product-information/pegasys-epar-product-information_en.pdf
- Fachinformation (DE): https://www.ema.europa.eu/de/documents/product-information/pegasys-epar-product-information_de.pdf
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/pegasys

Mechanism (SmPC section 5.1): Pegylated interferon alfa-2a provides antiviral and antiproliferative activities characteristic of interferon alfa-2a.

## Label wording

- **Peginterferon alfa-2a** (Pegasys), Myeloproliferative neoplasms, any line: “Pegasys is indicated as monotherapy in adults for the treatment of polycythaemia vera.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/pegasys-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/drugs/peginterferon-alfa-2a